aspirin + clopidogrel + digoxin

Aspirin + clopidogrel + digoxin is a combination of three well-established small molecule drugs, each with distinct mechanisms of action and therapeutic roles in cardiovascular medicine. Aspirin is an antiplatelet agent that irreversibly inhibits cyclooxygenase-1 (COX-1), reducing thromboxane A2 production and thereby decreasing platelet aggregation. Clopidogrel is another antiplatelet drug that acts as a P2Y12 receptor antagonist, inhibiting ADP-mediated platelet activation and aggregation. Digoxin is a cardiac glycoside that increases myocardial contractility by inhibiting the sodium-potassium ATPase pump, leading to increased intracellular calcium in cardiac cells; it also exerts effects on atrioventricular conduction useful for controlling heart rate in atrial fibrillation. This triple combination may be used in select patients with complex cardiovascular disease—such as those with heart failure, arrhythmias (e.g., atrial fibrillation), or after acute coronary syndromes—where both rhythm control and prevention of thrombotic events are required. However, this regimen carries significant risk for drug-drug interactions and adverse effects such as bleeding (from dual antiplatelet therapy) or digoxin toxicity; thus, it requires careful monitoring[3][5][6][7][8].